Opinion: AIA Does Not Discriminate

The America Invents Act (AIA) was a step in the right direction for US competitiveness and open innovation.

Written byG. Nagesh Rao
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The National Portrait Gallery, located in the Old Patent Office Building in Washington, D.C.WIKIMEDIA, AUDEOver the past year there have been a number of articles written about the ever greater importance bestowed by the programmatic and policy endeavors of the US Patent and Trademark Office (USPTO) and the overall US intellectual property ecosystem. In particular, there has been much criticism of the changes imposed by the Leahy-Smith America Invents Act (AIA) passed in September 2011—including a recent opinion article in The Scientist by George Lewis, who argued that the new law “discriminates against academics and small biotechs.” Unfortunately most of the time, the issues presented to the public—and the basis of many of Lewis’s arguments—are either incorrect or missing key pieces of information to explain why the law operates in a particular fashion.

First, the passing of AIA did not result in a “first to file” system, as Lewis and others argue. Rather, the USPTO now adopts a modified “first inventor to file” system, which preserves some of the protocol matters of the former “first to invent” system, including the 1-year filing grace period and the need for the inventor to file the patent application with a fully “reduced to practice” invention—in other words, the proof of concept or a prototype has been developed. Thus, it is not possible for a non-inventor with a disposable income to swoop in and “steal” a patent from a true inventor who may need a little extra time to secure the necessary application funding while they go public with their initial conceptual ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies